Cambium Bio Limited has released a press release.
Regeneus partners with Defence to treat combat casualties
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Cambium Bio
- Regeneus to be granted key Progenza patent in Europe
- Regeneus Company Update Investor Webcast Presentation
- Half-Year Results and Business Update
- Appendix 4D and Half-Year Report
- Regeneus to be granted new patent to target pain in Japan
Later from Cambium Bio
- Appendix 4C - Quarterly
- Regeneus Announces Institutional Placement
- Regeneus Market Update
- Grant of ASX Waiver
- Preliminary Final Report
Follow Cambium Bio into a list and get an email when it puts out news.
Follow Cambium Bio